Eribuline Zentiva

Eribulin Mesylate is a chemotherapy drug used to treat certain types of cancer. It works by slowing or stopping cancer cell growth, often used in advanced breast cancer treatment.

Eribulin Mesylate is primarily used in the treatment of metastatic breast cancer. It is designed to target and disrupt the growth of cancer cells, helping to slow the progression of the disease. This medication is typically administered intravenously and is often considered when other treatments have not been effective.

Common effects of Eribulin Mesylate may include fatigue, nausea, and hair loss. Some patients may also experience peripheral neuropathy, which can cause numbness or tingling in the hands and feet. These effects can vary in severity and duration depending on the individual.

Eribulin Mesylate should be handled with care and administered by a healthcare professional. It is important to follow all safety guidelines when using this medication. Patients should be monitored regularly for any adverse reactions and should report any unusual symptoms to their healthcare provider immediately.

Eribulin Mesylate may interact with other medications, including those that affect the liver or bone marrow. It is important to inform your healthcare provider about all medications you are taking to avoid potential interactions. Alcohol and certain supplements may also affect the efficacy of this medication.